Lapatinib / ROS Cancer Research Results

Lap, Lapatinib: Click to Expand ⟱
Features:
Lapatinib is a tyrosine kinase inhibitor primarily used in the treatment of HER2-positive breast cancer, among other cancer types. Its mechanism of action involves binding to the intracellular ATP-binding sites of the HER1 (also known as EGFR) and HER2 receptors, thereby inhibiting their autophosphorylation and subsequent activation of downstream signaling pathways. The major pathways involved include:
-PI3K/AKT/mTOR Pathway
Inhibition of this pathway leads to reduced cell survival and proliferation, as it normally promotes growth and survival signals through downstream effectors.
-RAS/RAF/MEK/ERK (MAPK) Pathway
Blocking the activation of this cascade affects cell cycle progression, proliferation, and differentiation. In many cancers, dysregulation of this pathway contributes to uncontrolled growth.

By interfering with these signaling cascades, lapatinib can reduce tumor cell proliferation, induce apoptosis (programmed cell death), and potentially increase the sensitivity of tumor cells to additional therapeutic agents.

The induction of oxidative stress is one of the ways by which lapatinib can exert cytotoxic effects on cancer cells. Elevated ROS levels can damage cellular components, such as lipids, proteins, and DNA, thereby contributing to cell death.

Lapatinib — an orally administered small-molecule 4-anilinoquinazoline tyrosine kinase inhibitor that reversibly inhibits the intracellular kinase domains of HER2/ErbB2 and EGFR/ErbB1. It is a dual HER2/EGFR targeted anticancer drug, commonly abbreviated LAP or lapatinib, and is marketed as Tykerb. It is used primarily in HER2-positive advanced or metastatic breast cancer in combination with capecitabine or, in hormone-receptor-positive disease, letrozole. It remains marketed in Canada and has an active U.S. prescription-drug label. Its contemporary clinical role is generally later-line or context-dependent because newer HER2-directed agents provide superior efficacy in many treatment sequences.

Primary mechanisms (ranked):

  1. Direct inhibition of HER2/ErbB2 and EGFR/ErbB1 intracellular tyrosine kinase activity, preventing receptor autophosphorylation and ErbB-driven signaling.
  2. Suppression of PI3K/AKT/mTOR survival signaling downstream of HER-family receptors.
  3. Suppression of RAS/RAF/MEK/ERK proliferative signaling downstream of HER2/EGFR.
  4. Activation of FOXO3a and induction/stabilization of p27Kip1, promoting G1 cell-cycle arrest.
  5. Induction of apoptosis, including caspase/PARP-associated cell death, particularly in HER2-dependent cancer cells.
  6. Induction of autophagy secondary to HER2/AKT/mTOR suppression; in some HER2-positive models this contributes to lapatinib-induced apoptosis.
  7. Reduction of VEGF expression and angiogenic signaling through AKT/FOXO3a-related mechanisms.
  8. ROS and mitochondrial stress modulation as a secondary mechanism. HER2/PI3K inhibition can increase ROS in susceptible tumor cells, while CYP3A-mediated reactive metabolites can also produce mitochondrial oxidative stress and hepatotoxicity.
  9. NRF2 activation as a secondary/context-dependent oxidative-stress response rather than consistent NRF2 inhibition; particularly evident during hepatic/mitochondrial stress at higher experimental concentrations.
  10. Therapy sensitization and resistance modulation, including interactions with capecitabine/5-FU, endocrine therapy, trastuzumab and other treatments; acquired resistance can occur through HER3/EGFR/PI3K and other compensatory signaling.

Bioavailability / PK relevance: Oral absorption is incomplete and highly variable. At 1,250 mg/day, steady-state Cmax is approximately 2.43 µg/mL and AUC approximately 36.2 µg·h/mL; effective half-life is approximately 24 hours. Lapatinib is more than 99% protein bound and is extensively metabolized mainly by CYP3A4/3A5. Food markedly increases exposure, with approximately 3- to 4-fold increases in AUC depending on meal composition; consequently the approved regimen specifies administration at least one hour before or one hour after food. Strong CYP3A4 inhibitors and inducers can substantially alter exposure. Normal-brain penetration is poor because lapatinib is a P-gp/BCRP substrate, although penetration can be greater in disrupted brain metastases.

In-vitro vs systemic exposure relevance: Clinically observed total plasma Cmax at 1,250 mg/day corresponds roughly to low-micromolar total lapatinib concentrations, but more than 99% protein binding means free systemic concentrations are substantially lower. Experiments using approximately 0.1–1 µM may therefore be reasonably relevant to tumor exposure depending on tissue accumulation and protein conditions, whereas mechanistic studies using 5–20 µM, particularly NRF2/hepatotoxicity studies, substantially exceed typical unbound systemic exposure and should be interpreted primarily as mechanistic or toxicity models rather than direct therapeutic-equivalent exposure.

Clinical evidence status: Approved targeted therapy / Phase III RCT evidence / combination treatment. Lapatinib has demonstrated clinical benefit with capecitabine in previously treated HER2-positive advanced breast cancer and with letrozole in HR-positive/HER2-positive metastatic breast cancer. It remains marketed, including in Canada, but has largely moved to later-line or alternative use because trastuzumab deruxtecan, tucatinib-containing regimens and other newer HER2-directed therapies generally occupy preferred contemporary treatment positions. Major safety constraints include boxed-warning hepatotoxicity, diarrhea, reduced left-ventricular ejection fraction, QT prolongation, interstitial lung disease/pneumonitis, severe cutaneous reactions and clinically important CYP3A4-mediated drug interactions.

Lapatinib Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 HER2 and EGFR tyrosine kinase signaling HER2 phosphorylation ↓; EGFR phosphorylation ↓ HER-family signaling ↓ where receptors are expressed Blocks the initiating oncogenic receptor signal Primary direct pharmacologic mechanism. Lapatinib binds the intracellular ATP-binding kinase domains of HER2 and EGFR; HER2-driven tumors are the principal clinically validated target.
2 PI3K AKT mTOR survival signaling PI3K/AKT signaling ↓; mTOR signaling ↓ AKT signaling may ↓ (context-dependent) Survival and growth ↓ Major downstream consequence of HER2/EGFR blockade and a central mediator of growth inhibition and apoptosis.
3 RAS RAF MEK ERK proliferative signaling ERK phosphorylation ↓ ERK signaling may ↓ (context-dependent) Proliferation ↓ Major mitogenic pathway downstream of EGFR/HER2. Persistent or compensatory MAPK signaling can contribute to resistance.
4 FOXO3a p27 cell-cycle checkpoint FOXO3a ↑; nuclear p27Kip1 ↑; G1 arrest ↑ Not well characterized Cell-cycle progression ↓ AKT inhibition facilitates FOXO3a activity. Lapatinib increases p27 through transcriptional and post-translational mechanisms in HER2-overexpressing cells.
5 Apoptotic signaling Apoptosis ↑; cleaved caspase-3 ↑; cleaved PARP ↑; Bcl-xL ↓ Apoptotic injury may ↑ in susceptible tissues (context-dependent) Tumor-cell death ↑ Generally downstream of oncogenic survival-pathway suppression rather than a direct caspase-targeting action.
6 Autophagy and AMPK mTOR signaling Autophagy ↑; AMPK ↑; mTOR/p70S6K ↓ Not established Stress response and apoptosis facilitation In HER2-positive breast-cancer models, autophagy can contribute to rather than protect against lapatinib-induced apoptosis; effect remains model-dependent.
7 VEGF angiogenic signaling FOXO3a ↑; VEGF expression ↓ Not established Angiogenic drive ↓ Indirect consequence of HER2/AKT suppression and FOXO3a activation; secondary to the core receptor-kinase mechanism.
8 Mitochondrial ROS increase ROS ↑ (context-dependent); mitochondrial stress ↑ ROS ↑ and mitochondrial injury ↑ in hepatic toxicity models Oxidative stress and cell injury ↑ Secondary mechanism. HER2/PI3K pathway inhibition can increase ROS in tumor models; CYP3A-mediated reactive metabolites provide a separate mechanism for mitochondrial and hepatic oxidative injury.
9 NRF2 oxidative-stress response NRF2 ↑ (context-dependent) (high concentration only) NRF2 ↑ during hepatic oxidative stress (context-dependent) Adaptive antioxidant response ↑ Evidence supports NRF2 activation rather than a general NRF2 decrease. HepG2 studies report NRF2 stabilization and nuclear translocation at approximately 5 µM and NRF2-regulated gene induction mainly at 10 µM or above.
10 Therapy sensitization Chemosensitivity ↑; endocrine sensitivity ↑ (context-dependent) Normal-tissue toxicity may also ↑ with combinations Combination efficacy ↑ Clinically established combinations include capecitabine and letrozole. Preclinical interactions also occur with trastuzumab, radiotherapy and other agents, but sensitization is treatment- and tumor-dependent.
11 HER3 EGFR compensatory resistance HER3/EGFR/PI3K signaling ↑ during acquired resistance (context-dependent) Not applicable Lapatinib sensitivity ↓ Persistent HER-family signaling, heregulin/HER3 signaling, altered PI3K/AKT signaling and other adaptive pathways can bypass incomplete HER2/EGFR inhibition.
12 Clinical Translation Constraint Target dependence and resistance strongly influence response Hepatotoxicity ↑; cardiac dysfunction risk ↑; diarrhea ↑; QT prolongation risk ↑ Therapeutic window and current clinical positioning limited Absorption is variable, food markedly changes exposure, protein binding exceeds 99%, CYP3A4/3A5 metabolism creates major interaction potential, and CNS penetration into normal brain is poor. Newer HER2-directed therapies have reduced its preferred-line use.


ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy 
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination




Item ROS↑ NRF2 Condition Mechanism Class Remarks 



ROS">Piperlongumine
+++ ↓ [D][T] ROS-dominant






ROS">Shikonin
+++↓/±[D][T]ROS-dominant






ROS">Vitamin K3 (menadione)
+++↓[D]ROS-dominant






ROS">Copper (ionic / nano)
+++↓[Fe][F]ROS-dominant






ROS">Sodium Selenite
+++↓[D]ROS-dominant






ROS">Juglone
+++↓[D]ROS-dominant






ROS">Auranofin
+++↓[D]ROS-dominant






ROS">Photodynamic Therapy (PDT)
+++0[L][O₂]ROS-dominant






ROS">Radiotherapy / Radiation
+++0[O₂]ROS-dominant






ROS">Doxorubicin
+++↓[D]ROS-dominant






ROS">Cisplatin
++↓[D][T]ROS-dominant






ROS">Salinomycin
++↓[D][T]ROS-dominant






ROS">Artemisinin / DHA
++↓[Fe][T]ROS-dominant






ROS">Sulfasalazine
++↓[C][T]ROS-dominant






ROS">FMD / fasting
++↓[M][C][O₂]ROS-dominant






ROS">Vitamin C (pharmacologic)
++↓[Fe][D]ROS-dominant






ROS">Silver nanoparticles
++±[F][D]ROS-dominant






ROS">Gambogic acid
++↓[D][T]ROS-dominant






ROS">Parthenolide
++↓[D][T]ROS-dominant






ROS">Plumbagin
++↓[D]ROS-dominant






ROS">Allicin
++↓[D]ROS-dominant






ROS">Ashwagandha (Withaferin A)
++↓[D][T]ROS-dominant






ROS">Berberine
++↓[D][M]ROS-dominant






ROS">PEITC
++↓[D][C]ROS-dominant






ROS">Methionine restriction
+↓[M][C][T]ROS-secondary






ROS">DCA
+±[M][T]ROS-secondary






ROS">Capsaicin
+±[D][T]ROS-secondary






ROS">Galloflavin
+0[D]ROS-secondary






ROS">Piperine
+±[D][F]ROS-secondary






ROS">Propyl gallate
+↓[D]ROS-secondary






ROS">Scoulerine
+?[D][T]ROS-secondary






ROS">Thymoquinone
±±[D][T]Dual redox






ROS">Emodin
±±[D][T]Dual redox






ROS">Alpha-lipoic acid (ALA)
±↑[D][M]NRF2-dominant






ROS">Curcumin
±↑/↓[D][F]NRF2-dominant






ROS">EGCG
±↑/↓[D][O₂]NRF2-dominant






ROS">Quercetin
±↑/↓[D][Fe]NRF2-dominant






ROS">Resveratrol
±↑[D][M]NRF2-dominant






ROS">Sulforaphane
±↑↑[D]NRF2-dominant






ROS">Lycopene
0↑—Antioxidant






ROS">Rosmarinic acid
0↑—Antioxidant






ROS">Citrate
00—Neutral


Scientific Papers found: Click to Expand⟱
1389- BBR,  Lap,    Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS
- in-vitro, BC, BT474 - in-vitro, BC, AU-565
ChemoSen↑, Apoptosis↑, ROS↑, NRF2↓,
8169- Lap,    Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells
- in-vitro, Liver, HepG2
toxicity↑, mtDam↑, ROS↑, NRF2↑, GSH↑, GSSG↑, SOD2↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↑, 1,   GSSG↑, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↑, 2,   SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:109  Target#:275  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page